PT-141 (bremelanotide) began with an accidental self-injection at the University of Arizona and ended as FDA-approved Vyleesi. The research history spanning Melanotan II's discovery through the RECONNECT Phase 3 trials illuminates the melanocortin-4 receptor mechanism underlying sexual desire.